Roche's Eye Drug Faricimab Meets Primary Endpoint
By Cecilia Butini
Roche Holding AG said Monday that its eye treatment Faricimab
met its primary endpoint in two phase 3 studies.
The Swiss pharmaceutical major said the studies evaluated the
drug--an investigational bispecific antibody--in people with
neovascular age-related macular degeneration. They showed that
people receiving Faricimab injections at intervals of up to 16
weeks achieved noninferior visual acuity outcomes compared with use
of a different drug.
The company said Faricimab was generally well tolerated and
didn't present new or unexpected safety signals.
The two studies were Tenaya and Lucerne, Roche said.
Write to Cecilia Butini at email@example.com
(END) Dow Jones Newswires
January 25, 2021 01:29 ET (06:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.